AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06620822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310+Sintilimab
Description: The principle of CTLA-4 combined with PD-1 therapy is to fully relieve the inhibition of T cells by blocking both CTLA-4 and PD-1 immune checkpoints simultaneously.CTLA-4 inhibitors mainly work in the initial immune response stage by blocking the binding of CTLA-4 to B7 and enhancing the activation and proliferation of the initial T cells; whereas PD-1 inhibitors restore the anti-tumor activity of activated T cells by blocking the binding of PD-1 to its ligand PD-L1/PD-L2 and restoring their anti-tumor activity. and its ligand PD-L1/PD-L2 binding, lifting the functional inhibition of activated T cells and restoring their anti-tumor activity. Combination therapy can fully activate T-cells, improve the immune system\&amp;#39;s ability to recognize and attack tumors, enhance the anti-tumor immune response, and overcome the drug resistance of single therapy, thus improving the therapeutic effect.
Study NCT06620822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab
Description: Sindilizumab (Sintilimab) is a humanized anti-PD-1 monoclonal antibody that has demonstrated promising anti-tumor activity in several cancer types. It works by blocking the binding of PD-1 to its ligands, PD-L1 and PD-L2, thereby lifting the inhibition of T-cells and restoring the immune system\&#39;s killing function against tumor cells.
Study NCT06620523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CoQ10 1200 mg orally with Glutathione 1000 mg orally
Description: This is the intervention to assess efficacy of CoQ10 and Glutathione in prevention of cardiac surgery associated acute kidney injury
Study NCT06620523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group B: Placebo CoQ10 orally and Placebo Glutathione orally
Description: A placebo to exactly match the CoQ10 will be made with white gelatin empty capsules containing cellulose AND a placebo to exactly match the L-Glutathione will be made with white gelatin empty capsules containing cellulose.
Study NCT06622707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio taping
Description: Despite the increasing indications and new application techniques developed all over the world, it is believed that there is a need for evidence regarding the mechanisms of action and effectiveness of kinesio taping. As a result of the literature review, no study was found in which kinesio taping was applied for 72 hours as a non-pharmacological complementary method to reduce postoperative pain after cesarean section and increase postpartum comfort. In this study, it is planned to apply kinesiotaping for 72 hours after cesarean section.
Study NCT06622707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine clinical care
Description: As routine clinical care; Analgesic treatment protocol applied after cesarean section, postnatal care and discharge services are provided
Study NCT06622096 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of laboratory exams prescription
Description: Evaluation of laboratory exams prescription
Study NCT06710860 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ScreenTalk AI-based tailored communication intervention
Description: Participants in intervention group will receive the ScreenTalk AI-based intervention consisting of 3 sessions: (1) tailored messages: to provide CRC risk and screening recommendation based on family history and health belief assessment; (2) open dialogue: to communicate with users asking questions related to CRC risk and screening information, underpinned based on professional knowledge database and Large language models; (3) summary session: to provide a picture overview for easy review. The primary outcome (uptake of colonoscopy) will be measured at 3 months post-intervention (T1), 6 months post-intervention (T2), and 12 months post-intervention (T3).
Study NCT06731426 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBM-TAF
Description: CBM-TAF aims to modify TAF by training participants to adopt an interpretation style that is inconsistent with TAF (i.e., having unwanted thoughts is not morally equivalent to acting upon them and/or having unwanted thoughts does not increase the likelihood of feared events happening in real life). To personalize the training, CBM-TAF is designed to address 4 subtypes of OCD (as defined by Dimensional Obsessive-Compulsive Scale; Abramowitz et al., 2010), each of which targets either TAF-moral or TAF-likelihood. Participants will indicate two OCD subtypes that are most relevant to their experiences and only complete scenarios that correspond to their chosen subtypes. For each scenario, participants are instructed to enter a missing letter in a fragmented word and resolve its emotional ambiguity. After then, participants will answer a True/False question related to the given scenario to verify their comprehension and consolidate their acquisition of healthier interpretation style.
Study NCT06731426 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBM-SMP
Description: CBM-SMP is a comparable intervention to CBM-TAF (Siwiec et al., 2023), which aims to provide general education about stress and stress management techniques. It is identical to CBM-TAF in terms of its administration, except for the content of scenarios included in training sessions. For each scenario, participants are instructed to enter a missing letter in a fragmented word. After then, participants will answer a True/False question related to the given scenario in order to verify their comprehension.
Study NCT06730776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Topical medication
Description: It will be given to all participants in both groups (A\&B). The most commonly prescribed topical medication is lidocaine ointment 5% (Xylocaine jelly 2% or ointment 5%; AstraZeneca Pharmaceuticals LP, Wilmington, DE), applied as required for symptoms and for 30 minutes before sexual activity.
Study NCT06730776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical medication
Description: It will be given to all participants in both groups (A\&B). The most commonly prescribed topical medication is lidocaine ointment 5% (Xylocaine jelly 2% or ointment 5%; AstraZeneca Pharmaceuticals LP, Wilmington, DE), applied as required for symptoms and for 30 minutes before sexual activity.
Study NCT06730776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation
Description: This procedure will be applied for group B only. Before starting the first treatment session, each patient will be instructed briefly about the nature of the treatment to gain the patient's confidence and cooperation. This procedure will be performed by using TENS device on acupoints as the following: The participating woman will be placed in a relaxed comfortable supine position with her back well supported. The surface of the treated skin and the electrodes will be cleaned with alcohol wipe. The TENS protocol consists of a 30-minute weekly. session for 10 weeks of biphasic pulses with modulation 0/10-50 Hz of frequency and 300/100/3000 microseconds of pulse duration (s). The intensity parameter will be adapted individually according to each woman's perception, and modulated so that it is applied without discomfort, ranging between 10 and 100 mA (pulsing sensation) (Dionisi and Senatori ,2011)
Study NCT06730009 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SLOG + Allogeneic NK cell
Description: Drug: SLOG chemotherapy S-1, leucovorin, oxaliplatin, and gemcitabine (SLOG)~Biological:~Allogeneic Magicell-NK contains NK cells suspended in 100 mL of normal saline Ph I dose starts at 10 × 10\^8 cells (Cohort 1) and escalates to 20 × 10\^8 cells (Cohort 2).~Ph II dose will be determined lower than or equal to Ph I MTD/MFD.
Study NCT06730009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SLOG chemotherapy
Description: Drug: SLOG chemotherapy S-1, leucovorin, oxaliplatin, and gemcitabine (SLOG)
Study NCT06730503 — intervention group
Intervention type: DRUG
Intervention: Immune checkpoint inhibitor
Description: Observe a situation before and after immunotherapy
Study NCT04717713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: steroid injection
Description: steroid injection at surgical location
Study NCT04717713 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: saline injection at surgical location
Study NCT05296252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mind-wandering intervention
Description: Participants in this condition receive a brief introduction to the potential impact of mind-wandering (before learning, proactive), and are redirected to lesson if probe-caught mind-wandering are endorsed (during learning, reactive)
Study NCT05345769 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AM712(ASKG712)
Description: AM712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.
Study NCT04579445 — intervention group
Intervention type: OTHER
Intervention: Education on tailored Quality Improvement measures
Description: Centers will undergo an education on defined Quality of Care measures, with the aim to implement a standardized pathway which is reproducible, scalable and which will allow increased access. The implementation of these measures will help to reduce resource requirements, intensive care bed occupancy and overall length of hospital stay with uncompromised patient safety.
Study NCT06215469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amma Portable Scalp Cooling System (PSCS)
Description: The unit is a compact, mobile refrigeration unit which circulates liquid coolant at low pressure through a special cooling cap on the participant's head, administered during non-investigational, cancer treatment.
Study NCT06215469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Quality of Life (QoL) and device usage questionnaires
Study NCT05296252 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mind-wandering comparison
Description: Participants in this condition receive no introduction, and only redirection, and the redirection is random, not in reaction to mind-wandering
Study NCT03330067 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cold and dry CO2 pneumoperitoneum
Description: In this arm, patients undergo pneumoperitoneum by the insufflation of cold (19-21°C) and nonhumidified (0%) CO2.
Study NCT03330067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Warm and humidified CO2 pneumoperitoneum
Description: In this arm, patients undergo pneumoperitoneum by the insufflation of warmed (95° F) and humidified (95% relative humidity) CO2, using a Lexion Insuflow device.
Study NCT04761406 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phaeosol group
Description: In a double blind, randomized manner, 40 pre-menopausal females will ingest one of the following for 12 weeks:~Treatment 1 -Placebo (218 mg/d of 100% sunflower Oil) Treatment 2 - PhaeoSOL (218 mg/d)~Supplements will be prepared in softgel capsules for double blind administration by the sponsor.
Study NCT04761406 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: In a double blind, randomized manner, 40 pre-menopausal females will ingest one of the following for 12 weeks:~Treatment 1 -Placebo (218 mg/d of 100% sunflower Oil) Treatment 2 - PhaeoSOL (218 mg/d)~Supplements will be prepared in softgel capsules for double blind administration by the sponsor.
Study NCT06531772 — intervention group
Intervention type: DRUG
Intervention: Antitubercular Agents
Description: Full regimen of antitubercular drugs for 6 month period or longer as justified by patient condition
Study NCT05012397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAIN-32
Description: 260 mg once daily orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle
Study NCT06201455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEI+GT
Description: After a standard phacoemulsification with intraocular lens implantation (PEI) is performed. The viscoelastic substance will be injected into the anterior chamber again to maintain corneal rigidity. The surgical microscope will be adjusted to tilt 35-40° towards the patient's nasal side, and the patient's head position will be adjusted to tilt 35-40° accordingly. A viscoelastic substance will be applied to the corneal surface to facilitate direct visualization of the angle structures under a gonioscope. The Tanito Microhook will be inserted through the main incision into the anterior chamber, and under gonioscopic guidance, the nasal (or inferonasal) trabecular meshwork and the inner wall of Schlemm's canal will be incised, approximately 120° in extent (60° in each direction).
Study NCT06201455 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PEI+MED
Description: Participants assigned to control group will undergo routine PEI surgery. Postoperatively, the decision to administer anti-glaucoma medication is based on intraocular pressure (IOP) measurements, and the target IOP is set at 16 mmHg. The selection of medications is informed by the Asia Pacific Glaucoma Guidelines (Kugler Publications, 2016), while the target IOP reference is the European Glaucoma Guidelines.
Study NCT05217511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: NMES was performed using a portable machine.The negative electrodes were placed in the motor points of the following muscles: chest muscles (pectoralis major muscle fibres) and rectus abdominis muscles bilaterally. A second (positive) electrode was positioned distally to the first, at a site close to the muscle that was being electrically stimulated, totalling 1 channel with 2 electrodes for each muscle . Each NMES session lasted 30 min. The following parameters were used: 50 Hz frequency, pulse duration 300 ms, rise time 1 s, stimulus time (ON) 3 s, decay time 1 s, and relaxation time (OFF) 10 s. Intensity was increased until muscle contraction was visible or could be identified through palpation. In conscious patients, intensity was adjusted according to their tolerance.
Study NCT04756128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg
Description: Colchicine is an oral anti-inflammatory agent that is relatively inexpensive, readily available, and has been used for generations. Approved for treatment and prophylaxis of gout flares and Mediterranean fever, it is also used in a variety of other inflammatory conditions (e.g. pericarditis and diffuse vascular inflammation such as Behcet syndrome). Colchicine binds to tubulin causing depolymerization, which interferes with neutrophil chemotaxis, adhesion, and mobilization to sites of inflammation, and contributes to reduction in superoxide production; through interference of the NLRP3 inflammasome protein complex, colchicine inhibits IL-1b, IL-6, and IL-18 production.~For this study, patients enrolled in a colchicine containing arm will receive 0.6mg of colchicine BID (unless renal function/gastrointestinal issues require adjustments described in the protocol)
Study NCT04756128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Most well known as an opioid antagonist, or a treatment for alcohol dependence, naltrexone also possesses immunomodulatory effects. Seen exclusively at low doses, this attribute is being employed in the pain community as a novel anti-inflammatory agent that has been shown to reduce symptom severity in fibromyalgia, Crohn's disease, multiple sclerosis, and complex regional pain syndrome.~For this study, patients enrolled in a naltrexone-containing arm will take their daily dose of the medication (4.5mg) by oral suspension.
Study NCT06172348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritlecitinib
Description: Ritlecitinib 100 milligrams (mg) will be provided as either solution or capsule formulation (2 capsules of 50 mg)
Study NCT05299372 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Telemonitoring via Careportal®
Description: The question sets and overnight oximetry results will be monitored and screened by a call centre commissioned by the Liverpool Clinical Commissioning Group (LCCG). The call centre will screen the weekly data and contact clinicians where appropriate (i.e. NIV team, MND specialist nurse, or patient's GP). PVI data will be examined by NIV physiotherapists, where required, following the contact from LCCG to ensure the maximum benefits of NIV to patients.
Study NCT05302024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: Oral iguratimod (25 mg twice daily) for 12 weeks. Iguratimod is a new drug for the treatment of rheumatoid arthritis (RA) and osteoarthritis (OA), which was filed for marketing in Japan in 2003. It can significantly reduce the inflammatory response, not only selectively inhibit COX-2, but also inhibit the production of inflammatory cytokines, tumor necrosis factor, lymphocytes and immunoglobulins, and has an autoimmunomodulatory effect; it has a rapid onset of action, better efficacy and fewer adverse effects than existing drugs, and is effective in patients for whom other drugs are ineffective. It has been reported in the literature that in vitro iguratimod can inhibit the activity of nuclear factor-κB (NF-κB), which in turn inhibits the production of inflammatory cytokines (interleukin-1, interleukin-6, interleukin-8, tumor necrosis factor alpha). Iguratimod also interacts directly with mouse and human B cells in vitro to inhibit the production of immunoglobulins.
Study NCT06389929 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: In line with the skill they will determine for one of the applications in the Skill Checklists (Breastfeeding Education Skill Control Form, Breast Care and Giving Care to Mothers with Breast Engorgement Skill Control Form, Breast Self-Examination (KKMM) Training Skill Control Form) apply.
Study NCT06478732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: health services
Description: Implement comprehensive heart failure management for patients in the experimental group using the HeartMed-HF digital therapy
Study NCT04758546 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Screening criteria for weaning and minimal ventilatory settings for spontaneous breathing trial
Description: Aggressive screening criteria: Walsh Conservative screening criteria: Boles High minimal ventilatory settings: pressure Support 8 + positive end-expiratory pressure 5 Low minimal ventilatory settings: pressure support 5
Study NCT04758546 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Screening criteria for weaning and minimal ventilatory settings for spontaneous breathing trial
Description: Aggressive screening criteria: Walsh Conservative screening criteria: Boles High minimal ventilatory settings: pressure Support 8 + positive end-expiratory pressure 5 Low minimal ventilatory settings: pressure support 5
Study NCT05270473 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: uterine compressive sutures
Description: uterine compression sutures comaprison
Study NCT05188313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Intravenous administration of study drug
Study NCT05188313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Intravenous administration of study drug
Study NCT05188313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Intravenous administration of study drug
Study NCT05188313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenous administration of study drug
Study NCT05188313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Intravenous administration of study drug
Study NCT05188313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous administration of study drug
Study NCT05644535 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebrospinal fluid densitometry
Description: After obtaining the patient's cerebrospinal fluid specimen, the actual mass of the cerebrospinal fluid was measured by pipetting 1000 μL of cerebrospinal fluid specimen on an analytical balance using a pipette gun, and all specimens were measured three times and the average of the three times was taken as the final mass of 1000 μL of that specimen. After the mass measurement, the residual cerebrospinal fluid was disposed of as medical waste. The density of each specimen was obtained according to the density to mass conversion formula ρ=m/v.
Study NCT05468749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: Single 12 mg oral dose administered on Day 1
Study NCT05247892 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided S1 Radiofrequency stimulation
Description: Pulsed radiofrequency stimulation of the S1 dorsal root ganglia under ultrasound-guidance
Study NCT05247892 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopic-guided S1 Radiofrequency stimulation
Description: Pulsed radiofrequency stimulation of the S1 dorsal root ganglia under fluoroscopy-guidance
Study NCT05500482 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typhoid conjugate Vaccine
Description: TyphiBEV is a clear colourless monovalent vaccine containing 25 µg of Typhoid Vi polysaccharide manufactured using the Citrobacter freundii sensu lato3056 (Vi) and is conjugated to CRM 197 as a carrier protein. Sodium chloride and Phosphate buffer are used as a buffering agent in the vaccine formulation with 2-Phenoxyethanol as a preservative.
Study NCT05644535 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood routine examination
Description: After obtaining the patient's blood specimens, they were sent to the laboratory for blood routine examination.
Study NCT05644535 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood electrolyte examination
Description: After obtaining the patient's blood specimens, they were sent to the laboratory for blood electrolyte examination.
Study NCT05434715 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thyroidectomy
Description: removal of the thyroid gland